G Hubsher1, M Haider, M S Okun. 1. Department of Neurology, Center for Movement Disorders and Neurorestoration, Gainesville, FL, USA.
Abstract
OBJECTIVE: To explore how amantadine transitioned from an anti-flu drug to antiparkinsonian agent. METHODS: A review of the historical literature on the use of amantadine from 1966 to the present was performed. RESULTS: Amantadine was originally introduced and utilized as an antiviral medication. A single patient noticed relief in her Parkinson disease (PD) symptoms after taking amantadine for a flu infection, and this observation sparked an interest, and several important studies that eventually led to a new drug indication. CONCLUSION: Amantadine has over the years fallen out of favor as a drug to address influenza infection; however, it has become part of the arsenal utilized for early symptomatic treatment of PD, as well an option for treating dyskinesia.
OBJECTIVE: To explore how amantadine transitioned from an anti-flu drug to antiparkinsonian agent. METHODS: A review of the historical literature on the use of amantadine from 1966 to the present was performed. RESULTS:Amantadine was originally introduced and utilized as an antiviral medication. A single patient noticed relief in her Parkinson disease (PD) symptoms after taking amantadine for a flu infection, and this observation sparked an interest, and several important studies that eventually led to a new drug indication. CONCLUSION:Amantadine has over the years fallen out of favor as a drug to address influenza infection; however, it has become part of the arsenal utilized for early symptomatic treatment of PD, as well an option for treating dyskinesia.
Authors: Lukáš Tenora; Jesse Alt; Ranjeet P Dash; Alexandra J Gadiano; Kateřina Novotná; Vijayabhaskar Veeravalli; Jenny Lam; Quinn R Kirkpatrick; Kathryn M Lemberg; Pavel Majer; Rana Rais; Barbara S Slusher Journal: J Med Chem Date: 2019-03-29 Impact factor: 7.446
Authors: Tanya Chotibut; Richard W Davis; Jennifer C Arnold; Zachary Frenchek; Shawn Gurwara; Vimala Bondada; James W Geddes; Michael F Salvatore Journal: Mol Neurobiol Date: 2013-12-03 Impact factor: 5.590
Authors: Rosana Leiva; Matthew B Phillips; Andreea L Turcu; Esther Gratacòs-Batlle; Lara León-García; Francesc X Sureda; David Soto; Jon W Johnson; Santiago Vázquez Journal: ACS Chem Neurosci Date: 2018-06-01 Impact factor: 4.418
Authors: Anne Corbett; James Pickett; Alistair Burns; Jonathan Corcoran; Stephen B Dunnett; Paul Edison; Jim J Hagan; Clive Holmes; Emma Jones; Cornelius Katona; Ian Kearns; Patrick Kehoe; Amrit Mudher; Anthony Passmore; Nicola Shepherd; Frank Walsh; Clive Ballard Journal: Nat Rev Drug Discov Date: 2012-11 Impact factor: 84.694